全文获取类型
收费全文 | 259747篇 |
免费 | 24797篇 |
国内免费 | 12408篇 |
专业分类
耳鼻咽喉 | 3712篇 |
儿科学 | 4594篇 |
妇产科学 | 3465篇 |
基础医学 | 42581篇 |
口腔科学 | 6888篇 |
临床医学 | 21201篇 |
内科学 | 37293篇 |
皮肤病学 | 5227篇 |
神经病学 | 10933篇 |
特种医学 | 7604篇 |
外国民族医学 | 223篇 |
外科学 | 26264篇 |
综合类 | 42055篇 |
现状与发展 | 70篇 |
预防医学 | 8161篇 |
眼科学 | 4261篇 |
药学 | 18680篇 |
44篇 | |
中国医学 | 6508篇 |
肿瘤学 | 47188篇 |
出版年
2024年 | 499篇 |
2023年 | 3609篇 |
2022年 | 6651篇 |
2021年 | 9258篇 |
2020年 | 8260篇 |
2019年 | 7961篇 |
2018年 | 8123篇 |
2017年 | 8849篇 |
2016年 | 9458篇 |
2015年 | 10715篇 |
2014年 | 15720篇 |
2013年 | 16235篇 |
2012年 | 14819篇 |
2011年 | 16637篇 |
2010年 | 13696篇 |
2009年 | 13109篇 |
2008年 | 13754篇 |
2007年 | 14320篇 |
2006年 | 13192篇 |
2005年 | 11983篇 |
2004年 | 10264篇 |
2003年 | 8936篇 |
2002年 | 7485篇 |
2001年 | 6760篇 |
2000年 | 5620篇 |
1999年 | 4905篇 |
1998年 | 4565篇 |
1997年 | 4120篇 |
1996年 | 3703篇 |
1995年 | 3198篇 |
1994年 | 2886篇 |
1993年 | 2332篇 |
1992年 | 1942篇 |
1991年 | 1763篇 |
1990年 | 1478篇 |
1989年 | 1282篇 |
1988年 | 1206篇 |
1987年 | 963篇 |
1986年 | 875篇 |
1985年 | 1142篇 |
1984年 | 963篇 |
1983年 | 679篇 |
1982年 | 715篇 |
1981年 | 592篇 |
1980年 | 501篇 |
1979年 | 382篇 |
1978年 | 269篇 |
1977年 | 200篇 |
1976年 | 161篇 |
1975年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
82.
Huda Mohammed Alkreathy Mayson H. Alkhatib Safaa Ahmed Al Musaddi Khadijah Saeed A. Balamash Nadia Nour Osman Aftab Ahmad 《Clinical and experimental pharmacology & physiology》2019,46(5):496-505
Doxorubicin (DOX) is the most commonly used anticancer drug; however, it has limited use because prolonged administration may result in severe cardiotoxicity. Simvastatin (SIM), generally prescribed for hypercholesterolaemia, has also shown salubrious results in the monotherapy or combinational drug therapy of different cancers in various models. Nanoparticle drug delivery systems are a novel way of improving therapeutics and also improving the absorption and specificity of drugs towards tumour cells. In this study, we exploited this technology to increase drug specificity and minimize imminent adverse effects. In this study, the antitumour activity of the combination formulas of DOX and SIM, either loaded in water (DOX‐SIM‐Solution) or nanoemulsions (NEs) (DOX‐SIM‐NE), was evaluated in a Swiss albino mouse model of Ehrlich ascites carcinoma. The anticancer effect was assessed by quantifying the change in body weight, mean survival time, and percent increase in lifespan (%ILS), determining haematological and serum biochemical parameters (liver function test, kidney function test and lipid profile parameters) as well as studying the histopathological alterations in liver tissues. We observed a clear increase in %ILS of the DOX‐SIM‐Solution group (265.30) that was double the %ILS of the DOX‐SIM‐NE group (134.70). However, DOX‐SIM‐NE had a non‐toxic effect on the haematological parameters, whereas DOX‐SIM‐Solution increased the levels of haemoglobin and lymphocytes. Furthermore, the encapsulation of SIM and DOX into NEs improved the levels of all serum biochemical parameters compared to the DOX‐SIM‐Solution. A reduction in the side effects of DOX‐SIM‐NE on the liver was also established using light microscopy, which revealed that the morphologies of the hepatocytes of the mice were less affected by administration of the DOX‐SIM‐NE treatment than with the DOX‐SIM‐Solution treatment. The study showed that incorporating SIM into the DOX‐loaded‐NE formulation remarkably improved its efficiency and simultaneously reduced its adverse effects. 相似文献
83.
BackgroundComplete surgical removal is currently considered to be the best treatment option for pulmonary sarcomatoid carcinoma (PSC) especially in early stage operable disease; however, the reported recurrence-free survival is low. Benefits of adjuvant chemotherapy in PSC patients are still controversial, and there is no obvious agreement on the optimal treatment modalities of this disease. Therefore, we aimed to investigate the prognosis in terms of overall survival (OS) in patients with PSC who received adjuvant chemotherapy.MethodsThe review protocol was registered in PROSPERO (CRD42022306084). Patients with PSC who underwent surgical therapy with or without adjuvant chemotherapy were included into the meta-analysis. Hazard ratios (HR) with 95% confidence intervals (CIs) for OS were pooled and ROBINS-I tool was used to assess risk of bias of the included studies.ResultsWe identified four retrospective cohort studies with 6768 records from MEDLINE, Embase, and CENTRAL databases up to 9th September 2021, and altogether 1835 patients were included to the analysis. The present meta-analysis shows that patients receiving adjuvant chemotherapy had a significantly longer OS than patients who underwent surgical treatment alone (HR = 0.5657, 95%CI: 0.4391–0.7290, p < 0.0001).ConclusionsDespite the limited information on the chemotherapy regimens in the included studies, patients with PSC may benefit from adjuvant chemotherapy. More publications are required to evaluate and compare efficient adjuvant chemotherapy protocols in PSC cases. 相似文献
84.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
85.
86.
87.
88.
《International journal of oral and maxillofacial surgery》2021,50(11):1422-1428
It is clinically challenging to identify oral leukoplakias that have a high risk of undergoing malignant transformation. The aim of this retrospective study was to elucidate the associations between malignant transformation of oral leukoplakias and various clinicopathologic factors. Patients with a diagnosis of clinical oral leukoplakia, verified through histopathologic examination and with access to digital images of the lesion, were retrospectively included for the period 2003–2013. Using the clinical images, all lesions were re-evaluated regarding diagnosis and clinical subtype. Of the 234 included patients, with a median follow-up of 9 years, 27 (11.5%) developed oral squamous cell carcinoma. Among the clinicopathologic factors investigated, non-homogeneous oral leukoplakia (OL), OL with dysplasia, and OL localized to the tongue showed statistically significant increased rates of malignant transformation in the multivariate Cox regression analysis. Non-homogeneous OL showed a 15.2-times higher transformation rate than homogenous OL (P < 0.001). Dysplastic leukoplakias developed into carcinomas 2.4-times more often than did non-dysplastic leukoplakias (P = 0.048). OL located on the tongue showed a 2.8-times higher malignant transformation rate than OLs at other oral locations (P = 0.018), when other locations were combined into one group. Non-homogeneous OL, OL with dysplasia, and OL localized to the tongue have higher transformation rates. 相似文献
89.
目的 探讨人格特征对喉鳞状细胞癌(LSCC)患者术后近期心理健康状况的影响。方法 纳入2017年1月—2019年12月在湖北省肿瘤医院行手术治疗的119例男性LSCC患者,术后5~7 d采用SCL-90、SAS、SDS自评量表评估术后心理状态,采用EPQ问卷测评患者的人格特征。多元线性逐步回归方法分析LSCC患者术后近期SAS和SDS评分的影响因素。结果 男性LSCC患者术后SCL-90、SAS、SDS得分显著高于中国常模(P≤0.05),EPQ中精神质(P)量表和神经质(N)量表得分高于中国常模(P<0.01)。男性LSCC患者术后躯体化、强迫、焦虑、抑郁、敌对、恐怖、偏执、精神病性因子得分均显著高于中国常模(P<0.05)。家庭收入、手术方式、术后近期是否行放化疗、P和N人格特征是术后SAS评分的影响因素(均P<0.01);家庭收入、手术方式、术后近期是否行放化疗和N人格特征是术后SDS评分的影响因素(P<0.01)。结论 LSCC患者术后近期存在抑郁、焦虑等心理障碍;具有P和N人格特征;家庭收入、手术方式、术后近期是否行放化疗以及P和N人格特征是影响术后SAS及SDS评分的独立危险因素。 相似文献
90.